Navigation Links
Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
Date:10/14/2008

MOUNTAIN VIEW, Calif., Oct. 14 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., applauds the three winners of the 2008 Nobel Prize in Chemistry; Drs. Osamu Shimomura, Martin Chalfie, and Roger Y. Tsien, for the discovery and development of the green fluorescent protein (GFP) and a wide array of related fluorescent proteins. The application of fluorescent proteins as a research tool has revolutionized life science research and biotechnology: they enable researchers to monitor cellular activity in real time, characterize gene expression, and localize specific proteins, organelles, or cells of interest. Thus, fluorescent proteins have facilitated many groundbreaking discoveries in cell biology over the past decade.

"As a long-standing leader in the fluorescent protein field, Clontech is proud to have been the first company to commercialize the GFP technology that was developed by Dr. Chalfie and Dr. Douglas Prasher, enabling GFP to be used as a tool for cell biology research. Currently, we offer many fluorescent proteins that build upon the work of these three exceptional scientists, including the Fruit Fluorescent Proteins developed by Dr. Tsien," said Carol Lou, General Manager of Clontech Laboratories, Inc.

GFP was initially discovered and characterized by Dr. Shimomura, who isolated it from the jellyfish Aequorea victoria and discovered that it glowed bright green under ultraviolet light. Dr. Chalfie applied GFP to biological research, using it as a visual genetic tag to study biological phenomena in the bacterium Escherichia coli and the model organism Caenorhabditis elegans. Dr. Roger Y. Tsien, a Howard Hughes Medical Institute Investigator of the University of California, San Diego, furthered our general understanding of how GFP fluoresces and has engineered many fluorescent proteins, spanning a wide spectrum of colors not found in nature. The use of these different colored variants has enabled scientists to follow several different biological processes at the same time.

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc. develops, produces, and markets leading-edge biological products to the life science market worldwide. Clontech has approximately 2,000 products that enable life science researchers to study genes, their products, and their cellular function through the use of innovative and powerful tools for gene cloning, labeling, and expression; as well as for elucidating protein:protein interactions; isolating and purifying DNA and proteins; and conducting a wide variety of PCR experiments. Clontech is a wholly-owned subsidiary of Takara Bio Inc. For more information visit http://www.clontech.com

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com


'/>"/>
SOURCE Clontech Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
2. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
3. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
4. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
5. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
6. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
7. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
8. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
9. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Nordion, a standalone business of ... welcome today,s award by the United States Department ... of the Phase II cooperative agreement funding to ... the University of Missouri Research Reactor Center (MURR ... the establishment of a new, reliable supply of ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication ... - Global Forecast to 2026", published by MarketsandMarkets, the global market size was ... by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... AUSTIN, Texas , Dec. 7, 2016 /PRNewswire/ ... development of revolutionary immunogene therapy treatments, today announced ... healthcare practice within a leading strategic communications and ... strategic communications program. The program will combine investor ... the objective of raising the profile of Genprex ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, ... developing breakthrough immune modulatory medicines, announced today the initiation ... lead therapeutic candidate, LYC-30937- E nteric C oated, ... skin disease that is estimated to affect as many ... , with approximately 1.5 - 3 million cases ...
Breaking Biology Technology:
(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
Breaking Biology News(10 mins):